Discovery and Design of Novel HSP90 Inhibitors Using Multiple Fragment‐based Design Strategies
Authors:
- 11 July 2007
- journal article
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 70 (1) , 1-12
Abstract
The molecular chaperone HSP90 has been shown to facilitate cancer cell survival by stabilizing key proteins responsible for a malignant phenotype. We report here the results of parallel fragment‐based drug design approaches in the design of novel HSP90 inhibitors. Initial aminopyrimidine leads were elaborated using high‐throughput organic synthesis to yield nanomolar inhibitors of the enzyme. Second site leads were also identified which bound to HSP90 in two distinct conformations, an ‘open’ and ‘closed’ form. Intriguingly, linked fragment approaches targeting both of these conformations were successful in producing novel, micromolar inhibitors. Overall, this study shows that, with only a few fragment hits, multiple lead series can be generated for HSP90 due to the inherent flexibility of the active site. Thus, ample opportunities exist to use these lead series in the development of clinically useful HSP90 inhibitors for the treatment of cancers.Keywords
This publication has 25 references indexed in Scilit:
- A decade of fragment-based drug design: strategic advances and lessons learnedNature Reviews Drug Discovery, 2007
- Heat Shock Protein 90: A Unique Chemotherapeutic TargetSeminars in Oncology, 2006
- SAR by NMR: An Analysis of Potency Gains Realized Through Fragment‐linking and Fragment‐elaboration Strategies for Lead Generation2006
- A biochemical rationale for the anticancer effects of Hsp90 inhibitors: Slow, tight binding inhibition by geldanamycin and its analoguesProceedings of the National Academy of Sciences, 2006
- Crystal structure of an Hsp90–nucleotide–p23/Sba1 closed chaperone complexNature, 2006
- Structures of the N-Terminal and Middle Domains of E. coli Hsp90 and Conformation Changes upon ADP BindingStructure, 2005
- A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitorsNature, 2003
- NMR-Based Screening of Proteins Containing 13C-Labeled Methyl GroupsJournal of the American Chemical Society, 2000
- Structural Basis for Inhibition of the Hsp90 Molecular Chaperone by the Antitumor Antibiotics Radicicol and GeldanamycinJournal of Medicinal Chemistry, 1999
- Discovering High-Affinity Ligands for Proteins: SAR by NMRScience, 1996